Relapsed or Refractory B-cell Non-Hodgkin’s Lymphoma Market Outlook

Thelansis’s “Relapsed or Refractory B-cell Non-Hodgkin’s Lymphoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Relapsed or Refractory B-cell Non-Hodgkin’s Lymphoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Relapsed or Refractory B-cell Non-Hodgkin’s Lymphoma Overview

Relapsed or refractory B-cell non-Hodgkin’s lymphoma (r/r B-NHL) encompasses a heterogeneous group of lymphoid malignancies — including diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and marginal zone lymphoma — that recur or fail to achieve remission following initial chemoimmunotherapy. Pathobiological resistance drivers include BCL-2 overexpression, MYC rearrangements, tumour microenvironment immunosuppression, and acquired apoptotic pathway mutations. Restaging PET-CT, repeat biopsy for histological transformation, and molecular profiling guide therapeutic decision-making. CAR-T therapies — axicabtagene ciloleucel and lisocabtagene maraleucel — have supplanted autologous stem cell transplantation as the preferred second-line standard for primary refractory or early-relapsing DLBCL. Bispecific antibodies represent a transformative off-the-shelf immunotherapeutic advance — epcoritamab and glofitamab for r/r DLBCL, and mosunetuzumab specifically for r/r follicular lymphoma. Zanubrutinib and acalabrutinib are the definitive preferred covalent BTK inhibitors for mantle cell and marginal zone lymphoma, with pirtobrutinib — a non-covalent BTK inhibitor — serving as critical salvage therapy in BTK inhibitor-pretreated MCL. Tafasitamab-lenalidomide and polatuzumab vedotin-based regimens expand options in transplant-ineligible DLBCL. Prognosis varies with histological subtype and remission depth; clinical trial participation, multidisciplinary evaluation, and patient-centred palliative integration are indispensable.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025–2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)